The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,007
Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 245
PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.122 · Cited by 246
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Levitt, P., & Campbell, D. B. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37934 · Cited by 234
Simultaneous Identification of Multiple Driver Pathways in Cancer
Leiserson, M. D. M., Blokh, D., Sharan, R., & Raphael, B. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003054 · Cited by 240
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 236
Role of microRNA in anticancer drug resistance
Zheng, T., Wang, J., Chen, X., & Liu, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24782 · Cited by 234
Biology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 230
Karachaliou, N., Mayo, C., Costa, C., Magrí, I., Giménez-Capitán, A. A., Molina‐Vila, M. Á., & Rosell, R. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.007 · Cited by 241
Clinical next‐generation sequencing in patients with non–small cell lung cancer
Hagemann, I. S., Devarakonda, S. H. K., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., et al. (2014) · Cancer · doi:10.1002/cncr.29089 · Cited by 232
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W. J., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230
Self-citationAn integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D. A., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szőke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 232
Self-citationPI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 237
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Iglesias, V. S., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 233
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 234
Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 236
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0781 · Cited by 220
Cho, W. C. S., Chow, A. S. C., & Au, J. S. K. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.039 · Cited by 225
Calcium channel diversity: multiple roles of calcium channel subunits
DOLPHIN, A. C. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.06.006 · Cited by 224
Suda, K., Tomizawa, K., & Mitsudomi, T. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9209-4 · Cited by 226
Lung cancer in never smokers: The role of different risk factors other than tobacco smoking
Corrales, L., Rosell, R., Cardona, A. F., Martin, C. M., Zatarain-Barrón, Z. L., & Arrieta, O. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102895 · Cited by 226
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“MET mutations have been observed in about 5% of treatment-naive NSCLC [88], mainly within exons 2 and 14, outside of the kinase domain.”
BackgroundALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220
Translating Tumor Antigens into Cancer Vaccines
Buonaguro, L., Petrizzo, A., Tornesello, M. L., & Buonaguro, L. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00286-10 · Cited by 229
Deep mutational scanning: assessing protein function on a massive scale
Araya, C. L., & Fowler, D. M. (2011) · Trends in biotechnology · doi:10.1016/j.tibtech.2011.04.003 · Cited by 219
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.010 · Cited by 217
Papadimitrakopoulou, V. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825493eb · Cited by 220
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 214
CellCharter reveals spatial cell niches associated with tissue remodeling and cell plasticity
Varrone, M., Tavernari, D., Santamaria‐Martínez, A., Walsh, L. A., & Ciriello, G. (2023) · Nature Genetics · doi:10.1038/s41588-023-01588-4 · Cited by 220
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma
Mann, K. M., Ward, J. M., Yew, C. C. K., Kovochich, A., Dawson, D. W., Black, M. A., Brett, B. T., Scheetz, T. E., Dupuy, A. J., Initiative, A. P. C. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202490109 · Cited by 210
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C. D., Brodie, S. A., Palleschi, A., Alloisio, M., Pariscenti, G., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002162 · Cited by 212
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S., Schultheis, A. M., Yu, H. A., Mandelker, D. L., Ladanyi, M., & Büttner, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 220
Self-citationTargeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Zhou, Q., Lui, V. W. Y., & Yeo, W. (2011) · Future Oncology · doi:10.2217/fon.11.95 · Cited by 217
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 211
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
Garg, M., Nagata, Y., Kanojia, D., Mayakonda, A., Yoshida, K., Keloth, S. H., Zang, Z. J., Okuno, Y., Shiraishi, Y., Chiba, K., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646240 · Cited by 212
Self-citationMolecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 211
Gibson, W. J., Høivik, E. A., Halle, M. K., Taylor-Weiner, A. N., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 211
Self-citationNF-κB inhibitors in treatment and prevention of lung cancer
Rasmi, R. R., Sakthivel, K. M., & Guruvayoorappan, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110569 · Cited by 212
Cremona, C. A., & Behrens, A. (2013) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 219
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
Brambilla, E. M., & Gazdar, A. F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00014009 · Cited by 223
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing
Liu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P. T., Cui, P., Hua, X., Ding, F. H., Lü, Y., James, M. A., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs148 · Cited by 209
Self-citationAnticancer Activity of the Cholesterol Exporter ABCA1 Gene
Smith, B., & Land, H. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.011 · Cited by 208
Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
Sato, M., Larsen, J. E., Lee, W., Sun, H., Shames, D. S., Dalvi, M. P., Ramirez, R. D., Tang, H., DiMaio, J. M., Gao, B., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0634-t · Cited by 209
Self-citationComprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers
Wang, Z., Li, B., Luo, Y.-X., Lin, Q., Liu, S., Zhang, X., Zhou, H., Yang, J., & Qu, L. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.035 · Cited by 209
The detection and implication of genome instability in cancer
Pikor, L. A., Thu, K. L., Vucic, E. A., & Lam, W. L. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9429-5 · Cited by 216
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Kim, Y.-W., Hammerman, P. S., Kim, J., Yoon, J.-A., Lee, Y., Sun, J., Wilkerson, M. D., Pedamallu, C. S., Cibulskis, K., Yoo, Y. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8556 · Cited by 208
Self-citationReduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M. Z., Saunders, R. E., Melnick, M. A., Gettinger, S. N., Walther, Z., Wurtz, A., Heynen, G. J. J. E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 201
Self-citationTrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma
Kupferman, M. E., Jiffar, T., El‐Naggar, A. K., Yılmaz, T., Zhou, G., Xie, T., Feng, L., Wang, J., Holsinger, F. C., Yu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2009.486 · Cited by 202
Liu, W., Xing, F., Iiizumi‐Gairani, M., Okuda, H., Watabe, M., Pai, S. K., Pandey, P. R., Hirota, S., Kobayashi, A., Mo, Y., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100190 · Cited by 190
PCK2 activation mediates an adaptive response to glucose depletion in lung cancer
Leithner, K., Hrzenjak, A., Trötzmüller, M., Moustafa, T., Köfeler, H. C., Wohlkoenig, C., Stacher, E., Lindenmann, J., Harris, A. L., Olschewski, A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.47 · Cited by 204
Cancer genome sequencing: a review
Mardis, E. R., & Wilson, R. K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp396 · Cited by 214
Self-citationTan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Self-citationNew therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Agostino, S. D. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 203
Identifying cancer driver genes in tumor genome sequencing studies
Youn, A., & Simon, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq630 · Cited by 200
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing eventsPreprint
Liu, J., Lee, W., Jiang, Z., Chen, Z., Jhunjhunwala, S., Haverty, P. M., Gnad, F., Guan, Y., Gilbert, H., Stinson, J., et al. (2012) · Genome Research · doi:10.1101/gr.140988.112 · Cited by 208
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B. K., Gu, Y., Hare, B. J., Johnson, M., Li, H. Y., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 204
Eichner, L. J., Brun, S. N., Herzig, S., Young, N. P., Curtis, S. D., Shackelford, D. B., Shokhirev, M. N., Leblanc, M., Vera, L. I., Hutchins, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.005 · Cited by 194
Molecular Pathways: HER3 Targeted Therapy
Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 200
Critical role of AMPK in redox regulation under glucose starvation
Ren, Y., & Shen, H. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101154 · Cited by 201
Self-citationATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma
Han, X., Li, F., Fang, Z., Gao, Y., Li, F., Fang, R., Yao, S., Sun, Y., Li, L., Zhang, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4261 · Cited by 194
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Chen, Z., Li, J., Lin, S., Cao, C., Gimbrone, N. T., Yang, R., Fu, D., Carper, M. B., Haura, E. B., Schabath, M. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85250 · Cited by 192
Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G., Abate, F., Ambesi‐Impiombato, A., Sánchez-Martín, M., Carpenter, Z., Penson, A., Pérez-García, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608420113 · Cited by 196
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194
Self-citationGenomic heterogeneity of multiple synchronous lung cancer
Liu, Y., Zhang, J. J., Lin, L., Yin, G., Zhang, J., Zheng, S., Beird, H. C., Wu, N., Lü, N., Mao, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms13200 · Cited by 189
Self-citationChronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis
Parris, B. A., O’Farrell, H. E., Fong, K. M., & Yang, I. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.54 · Cited by 196
Extracellular matrix component signaling in cancer
Multhaupt, H. A. B., Leitinger, B., Gullberg, D., & Couchman, J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.013 · Cited by 197
Targeting ATR in DNA damage response and cancer therapeutics
Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.002 · Cited by 197
Girard, N., Shen, R., Guo, T., Zakowski, M. F., Heguy, A., Riely, G. J., Huang, J. G., Lau, C., Lash, A., Ladanyi, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0644 · Cited by 191
Self-citationGenetic Changes in Squamous Cell Lung Cancer: A Review
Heist, R. S., Sequist, L. V. D., & Engelman, J. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824cc334 · Cited by 197
Xiao, H., Zhang, L., Zhou, H., Lee, J. M., Garon, E. B., & Wong, D. T. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.012112 · Cited by 192
The NF1 gene revisited - from bench to bedside
Yap, Y. S., McPherson, J. R., Ong, C. K., Rozen, S., Teh, B. T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q., & VARMUS, H. E. (2015) · eLife · doi:10.7554/elife.06907 · Cited by 188
Self-citationMultiple primary lung cancer: A literature review
Romaszko-Wojtowicz, A. M., & Doboszyńska, A. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/68631 · Cited by 190
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Prognostic and Predictive Biomarkers: Tools in Personalized Oncology
Nalejska, E., Mączyńska, E., & Lewandowska, M. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0077-9 · Cited by 202
LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling
Gao, Y., Xiao, Q., Ma, H.-M., Li, L., Liu, J., Feng, Y., Fang, Z., Wu, J., Han, X., Zhang, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004952107 · Cited by 190
Lung Cancer in the Era of Precision Medicine
Politi, K. A., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 190
Expanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 188
Self-citationNovel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A. M., Newell, E. W., Iyer, N. G., Lim, W., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 185
Papadimitrakopoulou, V. A., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., Gupta, S. K., Byers, L. A., Izzo, J. G., Gettinger, S. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0084 · Cited by 182
Self-citationThe GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J. L., Graeber, T. G., Parlati, F., Demo, S. D., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 187
Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000422 · Cited by 182
Fujino, T., Kobayashi, Y., Suda, K., Koga, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.023 · Cited by 186
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Tiong, K. H., Mah, L. Y., & Leong, C. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0886-7 · Cited by 181
Chen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01113 · Cited by 181
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Ishikawa, Y., Wistuba, I. I., Flieder, D. B., Franklin, W. A., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0264-ra · Cited by 176
Self-citationLung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options
Yousefi, M., Bahrami, T., Salmaninejad, A., Nosrati, R., Ghaffari, P., & Ghaffari, S. H. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0345-5 · Cited by 180
Mutational spectra of human cancer
Pfeifer, G. P., & Nia, A. B. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 180
Sebestyén, E., Zawisza-Álvarez, M., & Eyras, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1392 · Cited by 185
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 180
Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.010 · Cited by 176
Self-citationVignot, S., Frampton, G. M., Soria, J.-C., Yelensky, R., Commo, F., Brambilla, C., Palmer, G., Moro-Sibilot, D., Ross, J. S., Cronin, M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7737 · Cited by 175
Seder, C. W., Hartojo, W., Lin, L., Silvers, A. L., Wang, Z., Thomas, D. G., Giordano, T. J., Chen, G., Chang, A. C., Orringer, M. B., et al. (2009) · Neoplasia · doi:10.1593/neo.81582 · Cited by 172
Self-citationJohn, T., Kohler, D. M., Pintilie, M., Yanagawa, N., Pham, N., Li, M., Panchal, D., Hui, F., Meng, F., Shepherd, F. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2224 · Cited by 176
Zhang, Y., Sun, Y., Pan, Y., Li, C., Shen, L., Li, Y., Luo, X., Ye, T., Wang, R., Hu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2511 · Cited by 175
Self-citationThe genetics of nodal marginal zone lymphoma
Spina, V., Khiabanian, H., Messina, M., Monti, S. M., Cascione, L., Bruscaggin, A., Spaccarotella, E., Holmes, A. B., Arcaini, L., Lucioni, M., et al. (2016) · Blood · doi:10.1182/blood-2016-02-696757 · Cited by 181
Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y., Liu, X., Lim, C. H., Koh, T. P. T., Aung, Z. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02584-z · Cited by 173
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
Jones, S. J. M., Laskin, J. J., Li, Y. Y., Griffith, O. L., An, J., Bilenky, M., Butterfield, Y. S. N., Cezard, T., Chuah, E., Corbett, R., et al. (2010) · Genome biology · doi:10.1186/gb-2010-11-8-r82 · Cited by 174
The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma
Oricchio, E., Nanjangud, G. J., Wolfe, A. L., Schatz, J. H., Mavrakis, K. J., Jiang, M., Liu, X., Bruno, J., Heguy, A., Olshen, A. B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.035 · Cited by 181
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
